Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by 3burtcon Feb 14, 2021 1:27pm

133 Views

Post# 32564999

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nasdaq

Doesn't matter mugs, amalgamation doesn't happen unless company is on the move! Clearly they are still working on it. No way Dan takes I.P. out of protection unless the company is being sold! That's why your argument for dilution is bogus! Big pharma is smart and would rather own instead of rent. Anyone who sits back and does nothing to acquire ate will pay for generations to come!

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand